An observational study in HCC - Hepatocellular Carcinoma, sponsored by Mansoura University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Mansoura University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Carcinoma, Hepatocellular with a site in Egypt — 17 open to participants now, 22 under way, 2 of them phase 3. Carcinoma, Hepatocellular · Egypt.
Among the 53 studies in Carcinoma, Hepatocellular with a site in Egypt, this one is the 6th largest by planned enrollment of the 35 observational ones that give a count, is one of 7 that started in 2026, is one of 35 observational ones, reaches primary completion later than 19 of the 21 other live ones, and was the 52nd registered.
3,650 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.
Browse Carcinoma, Hepatocellular studies →17 of the 53 studies in Carcinoma, Hepatocellular with a site in Egypt are open now. Recruiting first, the newest first:
Minia University · Sites in Egypt
Ages 18+
AstraZeneca · Sites in Egypt, Kuwait, Morocco and 4 more countries
Tanta University · Sites in Egypt
Ages 18+
Tanta University · Sites in Egypt
Ages 18+
Tanta University · Sites in Egypt
Ages 18+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 7 · Phase 4 3
First in 2010; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 200 across 851 observational studies indexed under Carcinoma, Hepatocellular.
Median enrollment 105 across the 18 interventional studies, 110 across the 35 observational. Of the 23 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 53 have an industry lead sponsor. The 10 most frequent:
Mansoura University is the lead sponsor of 1,119 studies on the registry; 183 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Mansoura University has 3 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
4 of the studies in Carcinoma, Hepatocellular with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06621472Cairo UniversityRetrolaminar Block Versus Subcostal Transversus Abdominis Plane Block in Liver Resection Surgery | 2027-01-01 |
| NCT07669597Sohag Oncology CenterComparison of Atezolizumab/Bevacizumab Versus Durvalumab/Tremelimumab (STRIDE) Protocols in Locally Advanced or Metastatic Hepatocellular Carcinoma Among Patients in Sohag | 2027-03-01 |
| NCT07904494Assiut UniversityImmune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma | 2027-10-01 |
| NCT07650773AstraZenecaCHARM Hepatocellular Carcinoma MEA Study | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 53 studies in Carcinoma, Hepatocellular with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Real-world data from a single-center experience evaluating patients with hepatocellular carcinoma (HCC) receiving systemic therapies
This retrospective cohort study will be conducted at the Tropical Medicine Department of Mansoura University Hospitals, recruiting patients with advanced hepatocellular carcinoma (HCC) who will receive systemic therapy between June 2022 and November 2024. Eligible participants will include those with Child-Pugh class A liver function, ECOG performance status 0-1, and Barcelona Clinic Liver Cancer (BCLC) stage C, or stage B with diffuse, infiltrative, or extensive bilobar involvement, or progression after transarterial chemoembolization (TACE). Additional laboratory and clinical criteria will be required, such as adequate blood counts, liver and renal function, and absence of large or risky esophageal varices. Patients with Child-Pugh class B or C, early or terminal stage disease, or contraindications to systemic therapy such as active infections, autoimmune conditions, or severe comorbidities will be excluded.
Operationally, all patients will undergo comprehensive history taking, physical examination, radiological imaging (ultrasound, triphasic CT, or MRI), and laboratory testing, including liver function, renal function, virology markers, and tumor biomarkers such as alpha-fetoprotein (AFP). Follow-up assessments will be performed every three months using physical exams, imaging, and laboratory tests to monitor disease progression and treatment outcomes. Data will be systematically collected and analyzed using SPSS version 25, with qualitative variables expressed as frequencies and percentages, and quantitative data assessed for normality and described accordingly. Statistical tests such as Chi-square and correlation analyses will be applied to evaluate associations, with the ultimate aim of estimating progression-free survival and overall survival in this patient population.
Patients with HCC that are recruited to the tropical medicine inpatient department and outpatient clinics and are submitted to the inclusion and exclusion criteria from June 2022 to November 2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1. HCC patients receiving TKI (Sorafenib and Regrofenib 2. HCC patients receiving Atezolizumab with Bevacizumab 3. HCC patients receiving Tremelimumab with Durvalumab 4 -HCC patients With positive PCR HCV treating by DAAs with systemic therapy
This study also gives Durvalumab, Tremelimumab, Atezolizumab. No intervention listed here names it: that was found by reading the record.
overall survival (OS)
time from initiation of systemic therapy to death from any cause
Time frame: 1 year
treatment response
m-RESIST analysis of the patients as its categories * CR - Complete response Disappearance of all arterial enhancement in all target lesions * PR - Partial response ≥30% decrease in the sum of diameters of viable tumor * SD - Stable disease Neither sufficient decrease for PR nor sufficient increase for PD * PD - Progressive disease ≥20% increase in the sum of viable tumor diameters, with an absolute increase of ≥5 mm, or appearance of new lesions/other progression criteria
Time frame: 1 year
progression free survival (PFS)
time from initiation of systemic therapy to radiological diseasas progression or death from any cause , whichever occur first
Time frame: one year
efficacy of DAAs in treatment of HCV in patients with active HCV infection and HCC during receiving systemic therapy
treatment of HCV infection in patient with HCC and active HCV infection during receiving systemic therapy of HCC which will be assed by PCR done 12 w after the end of treatment , * SVR: HCV RNA remains undetectable 12 weeks after completing treatment. This is the standard definition of virologic cure. * Or non responder as HCV RNA is still detected after 12 w of complete treatment -how it will affect liver function
Time frame: 1 year
Side effects
adverse events related to systemic therapy of HCC
Time frame: 1 year
Plan to share: Undecided — Will be shared after reasonable request
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.